Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07291297) titled 'Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma' on Dec. 17, 2025.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Wake Forest University Health Sciences

Condition: Sarcoma Metastatic Sarcoma, Soft Tissue

Intervention: Drug: Metformin Hydrochloride ER

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: February 2026

Target Sample Size: 50

Countr...